HighTower Advisors’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

HighTower Advisors’s Portfolio SYRS Stock Details SYRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-14,898	Closed	-$3.42K	–	4099
2024 Q4	$3.42K	Hold	14,898	–	–	﹤0.01%	3647
2024 Q3	$32K	Sell	14,898 -450	-3%	-$1.62K	﹤0.01%	3466
2024 Q2	$79K	Buy	15,348 +431	+3%	+$2.27K	﹤0.01%	3251
2024 Q1	$80K	Sell	14,917 -87	-0.6%	-$602	﹤0.01%	3198
2023 Q4	$117K	Hold	15,004	–	–	﹤0.01%	3164
2023 Q3	$59K	Hold	15,004	–	–	﹤0.01%	3201
2023 Q2	$47K	Hold	15,004	–	–	﹤0.01%	3171
2023 Q1	$40K	Hold	15,004	–	–	﹤0.01%	3074
2022 Q4	$53K	Buy	+15,004	New	+$65.1K	﹤0.01%	3027

Other funds holding SYRS

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

BBA

Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return

1CM

1492 Capital Management Milwaukee, Wisconsin $339M AUM 120.53% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

HighTower Advisors's SYRS Position: Q1 2025 in Review

HighTower Advisors sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q1 2025, closing a stake of 14,898 shares — an estimated $3.42K sold.

HighTower Advisors first reported a position in SYRS in Q4 2022 and held it in 9 quarters. The position peaked at $117K in Q4 2023. 7 funds tracked by Wall St. Rank hold SYRS as of Q1 2025.

HighTower Advisors reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
HighTower Advisors sold 14,898 Syros Pharmaceuticals, Inc. Common Stock shares in Q1 2025, an estimated $3.42K.
HighTower Advisors first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q4 2022 and held it in 9 quarters.
HighTower Advisors's Syros Pharmaceuticals, Inc. Common Stock position peaked at $117K in Q4 2023.
7 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q1 2025.

Based on HighTower Advisors's 13F filing for Q1 2025, filed 13 May 2025.